A Q&A with Aletha Maybank, AMA’s chief health equity officer

AlexHogan/STATIntheaftermathofthepolicemurderofGeorgeFloydandsubsequentBlackLivesMatterprotestsacros SammyKimballforSTATCanNovavaxfinallygetitright?What’sa“triple-G”drug?AndisNovoNordisklosingground?We




knowledge

author：comprehensive    Page View：42
Alastair Grant/AP

LONDON — AstraZeneca said Thursday it would purchase the French firm Amolyt Pharma in a deal worth up to $1 billion, picking up a rare disease drug in a pivotal trial.

The acquisition includes an upfront payment of $800 million in cash, plus another $250 million if regulatory milestones are met. 

advertisement

AstraZeneca framed the deal for Amolyt, which has focused on treatments for rare endocrine diseases, as a boost for its own rare disease pipeline. 

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Venture capital firm's plans to take over Akron hospital face hurdles
Next article： Novavax promises a turnaround & Lilly roils the obesity market